Alto Neuroscience ANRO Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's common stock, shares authorized (in shares)?
- Alto Neuroscience (ANRO) reported common stock, shares authorized (in shares) of $500M in Q1 2026.
- How has Alto Neuroscience's common stock, shares authorized (in shares) changed year-over-year?
- Alto Neuroscience's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $500M to $500M.
- What is the long-term trend for Alto Neuroscience's common stock, shares authorized (in shares)?
- Over 2 years (2023 to 2025), Alto Neuroscience's common stock, shares authorized (in shares) has grown at a 210.1% compound annual growth rate (CAGR), from $52M to $500M.